Chemotherapy-Induced Nausea and Vomiting Pipeline: Emerging Therapies and Key Companies Reshaping CINV Management | DelveInsight

The therapeutic landscape for Chemotherapy-Induced Nausea and Vomiting (CINV), one of the most distressing side effects of cancer treatment, is evolving rapidly with a growing emphasis on targeted therapies and improved patient quality of life. CINV significantly affects treatment adherence and patient well-being, especially in those receiving highly or moderately emetogenic chemotherapies. Advances in neuroreceptor modulation and novel antiemetic strategies are driving innovation in this space.

Biopharmaceutical companies such as Heron Therapeutics, Helsinn Healthcare, Eisai Inc., CSPC Pharmaceutical Group, and Otsuka Pharmaceutical are at the forefront, developing therapies that target serotonin (5-HT3), neurokinin-1 (NK1), and dopamine receptors. These agents aim to prevent both acute and delayed phases of nausea and vomiting, offering more comprehensive control for cancer patients undergoing chemotherapy.

DelveInsight's "Chemotherapy-Induced Nausea and Vomiting - Pipeline Insight, 2025" provides an in-depth analysis of the clinical and preclinical development pipeline, highlighting emerging drug candidates, mechanisms of action, trial statuses, and regulatory outlooks. The report covers a wide range of novel formulations, including fixed-dose combinations, extended-release injectables, and CNS-penetrant agents.

The assessment further explores the CINV treatment pipeline by analyzing development trends across different clinical phases, classes of therapy, routes of administration, and trial geographies. It also sheds light on key unmet needs, strategic licensing deals, and regulatory designations that are shaping the future of CINV management. With promising agents in late-stage trials and advancements in precision supportive care, the CINV treatment paradigm is poised for meaningful transformation.

Interested in learning more about the current treatment landscape and the key drivers shaping the chemotherapy-induced nausea and vomiting pipeline? Click here: https://www.delveinsight.com/report-store/chemotherapy-induced-nausea-and-vomiting-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Chemotherapy-Induced Nausea and Vomiting Pipeline Report
• DelveInsight's chemotherapy-induced nausea and vomiting pipeline analysis depicts a strong space with 8+ active players working to develop 10+ pipeline drugs for chemotherapy-induced nausea and vomiting treatment.
• The leading chemotherapy-induced nausea and vomiting companies include Helsinn Healthcare SA, Acacia Pharma, Camurus, Benuvia Therapeutics, Aphios Corporation, Aphios Corporation, Zhuhai Beihai Biotech, and others are evaluating their lead assets to improve the chemotherapy-induced nausea and vomiting treatment landscape.
• Key Chemotherapy induced nausea and vomiting pipeline therapies in various stages of development include Fosnetupitant, APD403, CAM2047, Ondansetron sublingual, Zindol, Research programme: Cannabin0id Nano therapeutics, BH006, and others.
In March 2025, the National Cancer Institute (NCI) updated its PDQ summary on "Nausea and Vomiting Related to Cancer Treatment," detailing clinical trial evidence for olanzapine in CINV. Trials showed olanzapine, combined with 5-HT3 antagonists and dexamethasone, improved complete response rates (no vomiting, no rescue) for HEC, with significant nausea control (visual analog scale) across acute and delayed phases, though sedation was noted
• In September 2024, the FDA issued draft guidance on oncology multiregional clinical trials (MRCTs), supporting CINV trials by recommending designs that ensure data applicability to U.S. patients. While not CINV-specific, it facilitates global trials for antiemetics like NK1 or 5-HT3 receptor antagonists, critical for HEC and MEC regimens.

Request a sample and discover the recent breakthroughs happening in the chemotherapy-induced nausea and vomiting pipeline landscape @ https://www.delveinsight.com/report-store/chemotherapy-induced-nausea-and-vomiting-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chemotherapy-Induced Nausea and Vomiting Overview
Chemotherapy-induced nausea and vomiting (CINV) is a common and challenging side effect experienced by cancer patients undergoing chemotherapy. It results from the toxic effects of chemotherapy drugs on both the gastrointestinal system and the central nervous system. The severity and duration of CINV can differ greatly between patients, ranging from mild symptoms to debilitating nausea and vomiting. These symptoms often lead to a decrease in appetite, weight loss, dehydration, and a significant impact on daily activities and quality of life.

The causes of CINV are complex and multifactorial. Chemotherapy drugs can trigger nausea and vomiting by affecting areas of the brain like the chemoreceptor trigger zone and the vomiting center. They may also damage the gastrointestinal tract lining, contributing to these symptoms. Patient-specific factors, such as age, gender, previous motion sickness history, and genetic makeup, can influence susceptibility to CINV. The risk of developing CINV can also vary depending on the type, dosage, and schedule of chemotherapy drugs.

Find out more about chemotherapy-induced nausea and vomiting medication @ https://www.delveinsight.com/report-store/chemotherapy-induced-nausea-and-vomiting-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chemotherapy-Induced Nausea and Vomiting Treatment Analysis: Drug Profile
Fosnetupitant: Helsinn Healthcare SA
Fosnetupitant is an NK1 receptor antagonist developed to prevent chemotherapy-induced nausea and vomiting (CINV). It is a phosphorylated prodrug of netupitant, formulated for intravenous administration. Under a licensing agreement with Helsinn Healthcare SA since April 2011, Taiho holds exclusive development and marketing rights in Japan and has led clinical development. A Phase III trial comparing fosnetupitant (235 mg) to fosaprepitant (150 mg), both combined with palonosetron and dexamethasone, demonstrated its efficacy in patients undergoing highly emetogenic chemotherapy. The drug is currently in the registration stage for CINV treatment.

APD403: Acacia Pharma
APD403 is a novel formulation of the selective dopamine antagonist amisulpride, designed to prevent CINV in cancer patients. It is being developed in both intravenous form for acute CINV prevention and oral form for delayed CINV management. The drug is currently in Phase II development for this indication.

CAM2047: Camurus
CAM2047 is an extended-release, subcutaneous formulation of granisetron, intended for the treatment of both acute and delayed CINV. The therapy is in Phase I clinical development and aims to offer sustained relief through depot-based delivery.

Learn more about the novel and emerging chemotherapy-induced nausea and vomiting pipeline therapies @ https://www.delveinsight.com/report-store/chemotherapy-induced-nausea-and-vomiting-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chemotherapy-Induced Nausea and Vomiting Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Chemotherapy-Induced Nausea and Vomiting Pipeline Report
• Coverage: Global
• Key Chemotherapy Induced Nausea and Vomiting Companies: Helsinn Healthcare SA, Acacia Pharma, Camurus, Benuvia Therapeutics, Aphios Corporation, Aphios Corporation, Zhuhai Beihai Biotech Co., Ltd., and others.
• Key Chemotherapy Induced Nausea and Vomiting Pipeline Therapies: Fosnetupitant, APD403, CAM2047, Ondansetron sublingual, Zindol, Research programme: Cannabin0id Nano therapeutics, BH006, and others.

Dive deep into rich insights for drugs used for chemotherapy-induced nausea and vomiting treatment; visit @ https://www.delveinsight.com/report-store/chemotherapy-induced-nausea-and-vomiting-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Chemotherapy-Induced Nausea and Vomiting Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Chemotherapy-Induced Nausea and Vomiting Pipeline Therapeutics
6. Chemotherapy-Induced Nausea and Vomiting Pipeline: Late-Stage Products (Phase III)
7. Chemotherapy-Induced Nausea and Vomiting Pipeline: Mid-Stage Products (Phase II)
8. Chemotherapy-Induced Nausea and Vomiting Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.